Paloma Partners’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-2,770
Closed -$864K 2096
2021
Q2
$864K Buy
+2,770
New +$850K 0.02% 713
2020
Q4
Sell
-4,143
Closed -$1.15M 2392
2020
Q3
$1.15M Buy
4,143
+1,764
+74% +$508K 0.03% 658
2020
Q2
$575K Sell
2,379
-40
-2% -$8.03K 0.01% 1167
2020
Q1
$351K Sell
2,419
-17,493
-88% -$2.9M 0.02% 623
2019
Q4
$3.4M Buy
19,912
+10,682
+116% +$1.98M 0.05% 380
2019
Q3
$1.64M Buy
+9,230
New +$2M 0.03% 521
2019
Q2
Sell
-8,147
Closed -$2.16M 2294
2019
Q1
$2.33M Buy
+8,147
New +$2.71M 0.06% 385
2018
Q4
Sell
-1,379
Closed -$479K 1883
2018
Q3
$620K Sell
1,379
-372
-21% -$147K 0.01% 940
2018
Q2
$716K Buy
+1,751
New +$634K 0.01% 862
2017
Q3
Sell
-10,500
Closed -$1.5M 2548
2017
Q2
$1.5M Buy
10,500
+3,836
+58% +$516K 0.02% 945
2017
Q1
$834K Buy
6,664
+2,644
+66% +$306K 0.01% 1337
2016
Q4
$453K Buy
+4,020
New +$466K ﹤0.01% 1551
2016
Q3
Sell
-93,007
Closed -$10.2M 2213
2016
Q2
$10.2M Buy
93,007
+87,584
+1,615% +$8.71M 0.11% 100
2016
Q1
$514K Buy
+5,423
New +$458K 0.01% 1289
2015
Q4
Sell
-5,525
Closed -$512K 1987
2015
Q3
$512K Buy
+5,525
New +$487K 0.01% 1017

Other funds holding ABMD

Paloma Partners's ABMD Position: Q3 2021 in Review

Paloma Partners sold out of Abiomed Inc (ABMD) in Q3 2021, closing a stake of 2,770 shares — an estimated $864K sold.

Paloma Partners first reported a position in ABMD in Q3 2015 and held it in 15 quarters. The position peaked at $10.2M in Q2 2016. 498 funds tracked by Wall St. Rank hold ABMD as of Q3 2021.

  • Paloma Partners reported no remaining Abiomed Inc position as of Q3 2021 after selling out during the quarter.
  • Paloma Partners sold 2,770 Abiomed Inc shares in Q3 2021, an estimated $864K.
  • Paloma Partners first reported a position in Abiomed Inc in Q3 2015 and held it in 15 quarters.
  • Paloma Partners's Abiomed Inc position peaked at $10.2M in Q2 2016.
  • 498 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2021.

Based on Paloma Partners's 13F filing for Q3 2021, filed 15 Nov 2021.